2 results match your criteria: "1 University of Missouri-Kansas City School of Pharmacy[Affiliation]"
In Response to Letters to the Editor From the American Diabetes Association and Eli Lilly in Regard to: Insulin Concentration in Vials Randomly Purchased in Pharmacies in the United States: Considerable Loss in the Cold Supply Chain.
J Diabetes Sci Technol
September 2018
2 Science & Co, Neuss, Düsseldorf, Germany.
Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis.
Ann Pharmacother
May 2018
1 University of Missouri-Kansas City School of Pharmacy, Kansas City, MO, USA.
Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of ocrelizumab, a new B-cell-targeted therapy for multiple sclerosis (MS).
Data Sources: A comprehensive search of PubMed and OVID/MEDLINE was conducted using search terms ocrelizumab and multiple sclerosis using the date range of 1946 through October 2017.
Study Selection And Data Extraction: All English-language, human-subject articles related to ocrelizumab and MS were evaluated.